Relationships among serum receptor of nuclear factor-κB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: Osteoimmunity versus osteoinflammatory

Menopause

Volumn 16, Issue 5, 2009, Pages 950-955

  Nabipour, Iraj ^a   Larijani, Bagher ^b   Vahdat, Katayoun ^a   Assadi, Majid ^a   Jafari, Seyed Mojtaba ^a   Ahmadi, Esmaeil ^a   Movahed, Ali ^a   Moradhaseli, Farzad ^a   Sanjdideh, Zahra ^a   Obeidi, Narges ^a   Amiri, Zahra ^a  

^a BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; C reactive protein; Inflammation; Osteoprotegerin; Receptor activator of nuclear factor B ligand

Indexed keywords

C REACTIVE PROTEIN; COLLAGEN TYPE 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGE; ARTICLE; BONE DENSITY; BONE TURNOVER; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HUMAN; HUMAN EXPERIMENT; IMMUNITY; INFLAMMATION; LUMBAR SPINE; NORMAL HUMAN; POSTMENOPAUSE;

ABSORPTIOMETRY, PHOTON; AGE FACTORS; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DENSITY; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; IRAN; LINEAR MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; RANK LIGAND;

EID: 73349126412     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181a181b8     Document Type: Article

References (34)

1. Hofbauer LC, Kuhne CA, Viereck. V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact 2004; 4:268-275. (Pubitemid 39504354)
2. Gallagher JC. Advances in bone biology and new treatments for bone loss. Maturitas 2008;60:65-69.
3. Bucay N, Sarosi I, Dunstan. CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268. (Pubitemid 28213402)
4. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-319.
5. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008;473:139-146.
6. Ueland T, Yndestad A, Oie E, et al. Dysregulated osteoprotegerin/ RANK Hgand/RANK axis in clinical and experimental heart failure. Circulation 2005;111:2461-2468. (Pubitemid 40696134)
7. Ginaldi L, Di Benedetto MC, De Martinis M. Osteoporosis, inflammation and ageing. Immun Ageing 2005;2:14.
8. McCormick RK. Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility. Altern Med Rev 2007; 12:113-145.
9. Ding C, Parameswaran V, Udayan R, Burgess J, Jones G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption, in older adults: a longitudinal study. J. Clin Endocrinol Metab 2008;93:1952-1958. (Pubitemid 351656543)
10. Schett G, Kiechl S, Weger S, et al. High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 2006;166:2495-2501. (Pubitemid 44913235)
11. Pasco JA, Kotowicz MA, Henry MJ, et al. High-sensitivity C-reactive protein and fracture risk in elderly women. JAMA 2006;296:1353-1355. (Pubitemid 44427419)
12. Keams AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor KB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008;29:155-192.
13. Nabipour I, Larijani B. Beigi S, et al. Relationship among insulinlike growth factor I concentrations, bone mineral density, and biochemical markers of bone turnover in postmenopausal women: a population-based study. Menopause 2008;15:934-939.
14. World Health Organization. Assesment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva. Technical Report Series. 1994;843:1-129.
15. Mencej S, Albagha OM, Prezelj J, Kocjan T, Marc J. Tumour necrosis factor superfamily member 11 gene promoter polymorphisms modulate promoter activity and influence bone mineral density in postmenopausal women with osteoporosis. J Mol Endocrinol 2008;40:273-279. (Pubitemid 351865035)
16. Kim JG, Kim JH, Kim JY, et al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-K.B (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women, Menopause 2007;14:913-918.
17. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial, J Bone Miner Res 2009;24:153-161.
18. Liu JM, Zhao HY, Ning G, et al, Relationships between the changes of serum levels of OPG and RANKL with, age, menopause, bone biochemical markers and bone mineral density in Chinese women, aged 20-75. Calcif Tissue Int 2005;76:1-6. (Pubitemid 40228467)
19. Mezquita-Raya P, de la Higuera M, Garcia DF, et al. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women. Osteoporos Int 2005;16:1368-1374. (Pubitemid 41532089)
20. Kim JG, Kim JH, Lee DO, et al. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor KB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women. Menopause 2008; 15:357-362.
21. Uemura H, Yasui T, Miyatani Y, et al. Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in postmenopausal women. / Endocrinol Invest 2008; 31:163-168. (Pubitemid 351596978)
22. Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004;291:1108-1113. (Pubitemid 38541688)
23. Vega D, Maalouf NM, Sakhaee K. Clinical review: The role of receptor activator of nuclear factor-K.B (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007; 92:4514-4521. (Pubitemid 350223419)
24. Samelson. EJ, Broe KE, Demissie S, et al. Increased plasma osteoprotegerin concentrations are associated with indices of bone strength of the hip. J Clin Endocrinol Metab 2008;93:1789-1795. (Pubitemid 351656519)
25. Stern A, Laughlin. GA, Bergstrom. J, Barrett-Connor E. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor KB legend with bone mineral density in older adults: the Rancho Bernardo study. Eur J Endocrinol 2007;156:555-562. (Pubitemid 46796522)
26. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003;111: 1221-1230. (Pubitemid 36519939)
27. Hein GE, Meister M, Oelzner P, Franke S. sRANKL and OPG in serum, and synovial fluid of patients with, rheumatoid arthritis in. comparison to non-destructive chronic arthritis. Rheumatol Int 2008; 28:765-769.
28. Mazziotti G, Amato G, Sorvillo F, et al. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism. Eur J Endocrinol 2006;154:373-377.
29. Yamashita T, Yao Z, Li F, et al. NF-KB p50 and p52 regulate receptor activator of NF-KB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 2007;282:18245-18253. (Pubitemid 47100255)
30. Yao Z, Xing L, Qin C, Schwarz EM, Boyce BF. Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism. J Biol Chem 2008;283: 9917-9924.
31. Ganesan K, Teklehaimanot S, Tran TH, Asuncion M, Norris K. Relationship of C-reactive protein and bone mineral density in communitydwelling elderly females. J Natl Med Assoc 2005;97:329-333. (Pubitemid 40315936)
32. Bhupathiraju SN, Alekel DL, Stewart JW, et al. Relationship of circulating total homocysteine and C-reactive protein to trabecular bone in postmenopausal women. J Clin Densitom 2007;10:395-403.
33. Koh JM, Khang YH, Jung CH, et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and postmenopausal women: evidence for a link, between, systemic inflammation and osteoporosis. Osteoporos Int 2005;16:1263-1271.
34. Kim BJ, YU YM, Kim EN, Chung YE, Koh JM, Kim GS. Relationship between serum hsCRP concentration, and biochemical bone turnover markers in healthy pre- and postmenopausal women. Clin Endocrinol (Oxf) 2007;67:152-158.